This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Mar;13(3):225-7.

doi: 10.1016/S1470-2045(12)70001-3. Epub 2012 Jan 24.

Beyond first-line NSCLC therapy: chemotherapy or erlotinib?

Luis Paz-Ares¹

Affiliations

PMID: 22277836
DOI: 10.1016/S1470-2045(12)70001-3

Comment

Beyond first-line NSCLC therapy: chemotherapy or erlotinib?

Luis Paz-Ares. Lancet Oncol. 2012 Mar.

. 2012 Mar;13(3):225-7.

doi: 10.1016/S1470-2045(12)70001-3. Epub 2012 Jan 24.

Author

Luis Paz-Ares¹

Affiliation

¹ Instituto de Biomedicina de Sevilla and Hospital Universitario Virgen del Rocío, Seville, Spain. luis.pazares.sspa@juntadeandalucia.es

PMID: 22277836
DOI: 10.1016/S1470-2045(12)70001-3

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, Johannsdottir HK, Klughammer B, Gonzalez EE. Ciuleanu T, et al. Lancet Oncol. 2012 Mar;13(3):300-8. doi: 10.1016/S1470-2045(11)70385-0. Epub 2012 Jan 24. Lancet Oncol. 2012. PMID: 22277837 Clinical Trial.

Similar articles

Management of non-small cell lung cancer: focus on erlotinib. Foreword.
Cappuzzo F. Cappuzzo F. Drugs. 2012 Jun 19;72 Suppl 1:1-2. doi: 10.2165/1163029-S0-000000000-00000. Drugs. 2012. PMID: 22712791 No abstract available.
Second-line erlotinib for non-small-cell lung cancer.
Lorusso V, Cinieri S. Lorusso V, et al. Lancet Oncol. 2012 Apr;13(4):e141-2; author reply e142. doi: 10.1016/S1470-2045(12)70113-4. Epub 2012 Mar 30. Lancet Oncol. 2012. PMID: 22469123 No abstract available.
Optimising therapy for EGFR-addicted NSCLC: just the start.
Govindan R, Subramanian J. Govindan R, et al. Lancet Oncol. 2012 Mar;13(3):216-7. doi: 10.1016/S1470-2045(12)70037-2. Epub 2012 Jan 26. Lancet Oncol. 2012. PMID: 22285167 No abstract available.
[Erlotinib in the treatment of non-small cell lung cancer].
Ostoros G, Döme B. Ostoros G, et al. Magy Onkol. 2006;50(3):237-41. Epub 2006 Nov 12. Magy Onkol. 2006. PMID: 17099784 Review. Hungarian.
Treatment of non-small-cell lung cancer with erlotinib or gefitinib.
Cataldo VD, Gibbons DL, Pérez-Soler R, Quintás-Cardama A. Cataldo VD, et al. N Engl J Med. 2011 Mar 10;364(10):947-55. doi: 10.1056/NEJMct0807960. N Engl J Med. 2011. PMID: 21388312 Review.

See all similar articles

Cited by

Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.
Mao CQ, Xiong MH, Liu Y, Shen S, Du XJ, Yang XZ, Dou S, Zhang PZ, Wang J. Mao CQ, et al. Mol Ther. 2014 May;22(5):964-73. doi: 10.1038/mt.2014.18. Epub 2014 Feb 5. Mol Ther. 2014. PMID: 24496383 Free PMC article.
Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer.
Li N, Yang L, Ou W, Zhang L, Zhang SL, Wang SY. Li N, et al. PLoS One. 2014 Jul 16;9(7):e102777. doi: 10.1371/journal.pone.0102777. eCollection 2014. PLoS One. 2014. PMID: 25029199 Free PMC article.
Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system.
Li S, Liu Y, Rui Y, Tang L, Achilefu S, Gu Y. Li S, et al. Theranostics. 2018 Apr 3;8(10):2621-2633. doi: 10.7150/thno.24469. eCollection 2018. Theranostics. 2018. PMID: 29774063 Free PMC article.
MicroRNA-30a suppresses non-small-cell lung cancer by targeting Myb-related protein B.
Geng GJ, Yang YT, Jiang J, Yu XY, Fa XE. Geng GJ, et al. Exp Ther Med. 2018 Feb;15(2):1633-1639. doi: 10.3892/etm.2017.5559. Epub 2017 Nov 24. Exp Ther Med. 2018. PMID: 29434747 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information